I agree that this site is using cookies. You can find further informations here.
X
D'Erasmo L
3168  results:
OpenAccess-fulltext X
Search for persons X
?
1

Lipoprotein(a) Genotype Influences the Clinical Diagnosis o..:

Olmastroni E ; Gazzotti M ; Averna M...
info:eu-repo/semantics/altIdentifier/pmid/37183858.  , 2023
Link: https://hdl.handle.net/1..
 
?
2

Lomitapide hepatic safety: A long-term retrospective analys..:

J. Cegla ; D. Larrey ; L. D'Erasmo..
http://www.sciencedirect.com/science/article/pii/S2667089523000275.  , 2023
Link: https://doi.org/10.1016/..
 
?
3

Statin liver safety in non-alcoholic fatty liver disease: a..:

Pastori D ; Pani A ; Di Rocco A...
info:eu-repo/semantics/altIdentifier/pmid/34133035.  , 2022
Link: http://hdl.handle.net/11..
 
?
4

Lomitapide in the long-term real-world management of HoFH –..:

J. Cegla ; L. d'Erasmo ; K. Steward...
http://www.sciencedirect.com/science/article/pii/S2667089522000244.  , 2022
Link: https://doi.org/10.1016/..
 
?
5

Metabolic syndrome but not fatty liver-associated genetic v..:

Baratta F ; D'erasmo L ; Di Costanzo A...
info:eu-repo/semantics/altIdentifier/pmid/35327522.  , 2022
Link: http://hdl.handle.net/11..
 
?
6

Worldwide experience of homozygous familial hypercholestero..:

Tromp T. R ; Hartgers M. L ; Hovingh G. K...
info:eu-repo/semantics/altIdentifier/pmid/35101175.  , 2022
Link: http://hdl.handle.net/24..
 
?
7

Statin liver safety in non-alcoholic fatty liver disease: A..:

Pastori D ; Pani A ; Di Rocco A...
info:eu-repo/semantics/altIdentifier/pmid/34133035.  , 2022
Link: http://hdl.handle.net/21..
 
?
8

Statin liver safety in non-alcoholic fatty liver disease: A..:

Pastori D ; Pani A ; Di Rocco A...
info:eu-repo/semantics/altIdentifier/pmid/34133035.  , 2021
Link: https://hdl.handle.net/2..
 
?
9

Proprotein convertase subtilisin kexin type 9 inhibitors re..:

Cammisotto V ; Baratta F ; Castellani V...
info:eu-repo/semantics/altIdentifier/pmid/34281247.  , 2021
Link: https://hdl.handle.net/1..
 
?
10

Long-term efficacy of lipoprotein apheresis and lomitapide ..:

D'Erasmo L ; Gallo A ; Cefalu A. B...
info:eu-repo/semantics/altIdentifier/pmid/34496902.  , 2021
Link: http://hdl.handle.net/24..
 
?
11

Impact of prior statin use on clinical outcomes in COVID-19..:

Mitacchione G ; Schiavone M ; Curnis A...
info:eu-repo/semantics/altIdentifier/pmid/33390341.  , 2021
Link: http://hdl.handle.net/24..
 
?
12

Lomitapide does not alter PCSK9 and Lp(a) levels in homozyg..:

Lupo M. G ; Arcidiacono D ; Zaramella A...
info:eu-repo/semantics/altIdentifier/pmid/36644506.  , 2021
Link: http://hdl.handle.net/10..
 
?
13

Long-term efficacy of lipoprotein apheresis and lomitapide ..:

D'Erasmo L ; Gallo A ; Cefalù AB...
info:eu-repo/semantics/altIdentifier/pmid/34496902.  , 2021
Link: https://hdl.handle.net/1..
 
?
14

Long-term efficacy of lipoprotein apheresis and lomitapide ..:

D'Erasmo L ; Gallo A ; Cefalu A. B...
info:eu-repo/semantics/altIdentifier/pmid/34496902.  , 2021
Link: http://hdl.handle.net/10..
 
?
15

Efficacy and safety of lomitapide in homozygous familial hy..:

D'Erasmo, L ; Steward, K.A. (Kim) ; Cefalu, A B...
D'Erasmo , L , Steward , K A , Cefalu , A B , Di Costanzo , A , Boersma , E , Bini , S , Arca , M & Roeters van Lennep , J 2021 , ' Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia : the pan-European retrospective observational study ' , European Journal of Preventive Cardiology . https://doi.org/10.1093/eurjpc/zwab229/6491248.  , 2021
Link: https://pure.eur.nl/en/p..
 
1-15